(Reuters) -Lykos Therapeutics will lay off 75% of its workforce, or about 100 employees, and founder Rick Doblin will leave the board, the company said on Thursday, days after the U.S. FDA declined ...

Add Yahoo as a preferred source to see more of our stories on Google. Logo for the new Lykos Taverna coming to Darien Commons (Courtesy Lykos Taverna) DARIEN - Lykos Taverna, a Greek restaurant ...

Lykos Therapeutics is capping off an awful week with a massive reorganization, laying off about 75% of staff in the aftermath of an FDA rejection and the retraction of three research papers on the ...

The Food and Drug Administration declined Friday to approve an application to treat post-traumatic stress disorder using the drug midomafetamine, also known as MDMA or the street drug ecstasy, citing ...

Lykos Therapeutics, the manufacturer of midomafetamine (MDMA), which had been tested for PTSD treatment, will reduce its workforce by 75% after the FDA rejected the company’s new drug application. The ...

Following a poor showing for Lykos Therapeutics’ MDMA candidate for post-traumatic stress disorder at a recent FDA advisory committee meeting, the other shoe has dropped. Friday, the FDA declined to ...

Lykos Therapeutics announced it would cut 75% of its staff as part of a reorganization on Thursday afternoon. This announcement came less than one week after the Food and Drug Administration rejected ...

The journal Psychopharmacology has retracted three research papers on MDMA-assisted therapy due to alleged unethical conduct at study site In 2015, an unlicensed therapist who was part of the trial ...

(Reuters) - Lykos Therapeutics said on Thursday longtime CEO Amy Emerson would step down from the role, in the latest shakeup after the U.S. health regulator declined to approve its MDMA-based ...

Lykos Therapeutics, the developer of psychedelic drugs for mental health conditions that has been in financial difficulty, could get rescued by a former Tesla (TSLA) board member seen as close to Elon ...